How useful are measures of BMD and bone turnover?

References

• Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 2002;112:281–9
   PubMed Web of Science ®Google Scholar
• Black DM, Sarkar S, Mitlak B, Knickerbocker R, Cummings SR. What proportion of the effects of raloxifene (RLX) on vertebral fracture risk can be directly attributed to its bone mineral density (BMD) effects? J Bone Miner Res 1999;14\(Suppl 1):S158 [Abstract]
   Google Scholar
• Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 2002;17:1–10
   PubMed Web of Science ®Google Scholar
• Delmas PD, Seeman E. Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy. Bone 2004;34:599–604
   PubMed Web of Science ®Google Scholar
• Eastell R, Barton I, Hannon RA, Chines AA, Garnero P, Delmas PD. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003;18:1051–6
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services. Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville, MD: U.S. Department of Health and Human Services, Office of the Surgeon General, 2004
   Google Scholar
• Bouxsein ML. Bone quality: where do we go from here? Osteoporos Int 2003;14(Suppl 5):S118–27
   PubMed Web of Science ®Google Scholar
• National Osteoporosis Foundation. Osteoporosis: review of the evidence for prevention, diagnosis, and treatment and cost- effectiveness analysis. Osteoporos Int 1998;8(Suppl 4):S1–88
   Google Scholar
• U.S. Preventive Services Task Force. Screening for osteoporosis in postmenopausal women: recommendations and rationale. Ann Intern Med 2002;137:526–8
   Google Scholar
• Working Party Writing Group. Osteoporosis: clinical guidelines for prevention and treatment. Update on pharmacological interventions and an algorithm for management. London: Royal College of Physicians; 2001. pp.1–14
   Google Scholar
• Sambrook PN, Seeman E, Phillips SR, Ebeling PR. Preventing osteoporosis: outcomes of the Australian Fracture Prevention Summit. Med J Aust 2002;176(Suppl):S1–16
   Google Scholar
• Brown JP, Josse RG. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. Can Med Assoc J 2002;167(Suppl):S1–34
   Google Scholar
• National Institute for Clinical Excellence. TA087 Osteoporosis - secondary prevention – guidance. Available from www.nice.org. uk/page.aspx?o=241348 [Accessed March 9th, 2005]
   Google Scholar
• Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. Br Med J 1996;312:1254–9
   Google Scholar
• Adachi JD. The correlation of bone mineral density and biochemical markers to fracture risk. Calcif Tissue Int 1996;59(Suppl 1): S16–9
   PubMedGoogle Scholar
• Akesson K, Ljunghall S, Jonsson B, Sernbo I, Johnell O, Gardsell P, et al. Assessment of biochemical markers of bone metabolism in relation to the occurrence of fracture: a retrospective and prospective population-based study of women. J Bone Miner Res 1995;10:1823–9
   PubMed Web of Science ®Google Scholar
• Melton LJI, Crowson CS, O'Fallon WM, Wahner HW, Riggs BL. Relative contributions of bone density, bone turnover, and clinical risk factors to long-term fracture prediction. J Bone Miner Res 2003;18:312–8
   Google Scholar
• Akesson K, Vergnaud P, Gineyts E, Delmas PD, Obrant KJ. Impairment of bone turnover in elderly women with hip fracture. Calcif Tissue Int 1993;53:162–9
   Google Scholar
• Garnero P, Hausherr E, Chapuy M-C, Marcelli C, Grandjean H, Muller C, et al. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS prospective study. J Bone Miner Res 1996;11:1531–8
   Google Scholar
• Melton LJ III, Khosla S, Atkinson EJ, O'Fallon WM, Riggs BL. Relationship of bone turnover to bone density and fractures. J Bone Miner Res 1997;12:1083–91
   PubMedGoogle Scholar
• Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J, et al. Change in bone turnover and hip, non-spine and vertebral fracture in alendronate-treated women: the Fracture Intervention Trial. J Bone Miner Res 2004;19:1250–8
   PubMed Web of Science ®Google Scholar
• Hassager C, Colwell A, Assiri AMA, Eastell R, Russell RGG, Christiansen C. Effect of menopause and hormone replacement therapy on urinary excretion of pyridinium cross-links: a longitudinal and cross-sectional study. Clin Endocrinol 1992;37:45–50
   PubMed Web of Science ®Google Scholar
• Slemenda C, Hui SL, Longcope C, Johnston CC. Sex steroids and bone mass: a study of changes about the time of menopause. J Clin Invest 1987;80:1261–9
   PubMed Web of Science ®Google Scholar
• Garnero P, Sornay-Rendu E, Chapuy M-C, Delmas PD. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res 1996;11:337–49
   PubMed Web of Science ®Google Scholar
• Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994;79:1693–700
   Google Scholar
• Ross PD, Knowlton W. Rapid bone loss is associated with increased levels of biochemical markers. J Bone Miner Res 1998;13:297–302
   PubMed Web of Science ®Google Scholar
• Wasnich RD, Bagger YZ, Hosking D, McClung MR, Wu M, Yates J, et al. Changes in bone density and turnover after alendronate or estrogen withdrawal. Menopause 2004;11:622–30
   PubMedGoogle Scholar
• Bauer DC, Sklarin PM, Stone KL, Black DM, Nevitt MC, Ensrud KE, et al. Biochemical markers of bone turnover and prediction of hip bone loss in older women: the Study of Osteoporotic Fractures. J Bone Miner Res 1999;14:1404–10
   PubMed Web of Science ®Google Scholar
• Johansen JS, Riis BJ, Delmas PD, Christiansen C. Plasma BGP: an indicator of spontaneous bone loss and of the effect of oestrogen treatment in postmenopausal women. Eur J Clin Invest 1988;18:191–5
   PubMed Web of Science ®Google Scholar
• Riis BJ, Rodbro P, Christiansen C. The role of serum concentrations of sex steroids and bone turnover in the development and occurrence of postmenopausal osteoporosis. Calcif Tissue Int 1986;38:318–22
   Google Scholar
• Klotzbuecher C, Ross P, Landsman P, Abbott T, Berger M. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 2000;15:721–39
   Google Scholar
• Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling: emerging insights into the pathophysiology of osteoporosis. N Engl J Med 1995;332:305–11
   PubMed Web of Science ®Google Scholar
• Recker RR, Barger-Lux MJ. Bone remodeling findings in osteoporosis. In: Marcus R, Feldman D, Kelsey J, editors. Osteoporosis, 2nd edn. San Diego, CA: Academic Press; 2001. pp.59–70
   Google Scholar
• Mosekilde L. Age-related changes in bone mass, structure, and strength - effects of loading. Z Rheumatol 2000;59(Suppl 1):1–9
   PubMed Web of Science ®Google Scholar
• Boivin GY, Chavassieux PM, Santora AC, Yates J, Meunier PJ. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 2000;27:687–94
   Google Scholar
• Heaney RP, Yates AJ, Santora AC. Bisphosphonate effects and the bone remodeling transient. J Bone Miner Res 1997;12:1143–51
   PubMed Web of Science ®Google Scholar
• Siris ES, Miller PD, Barrett-Connor E, Faulkner K, Wehren LE, Abbott T, et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA 2001;286:2815–22
   Google Scholar
• Kanis JA, Johnell O, Oden A, Dawson A, de Laet C, Jonsson B. Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 2001;12:989–95
   PubMed Web of Science ®Google Scholar
• Hauge EM, Mosekilde LE, Melsen F, Frydenberg M. How many patients are needed? Variation and design considerations in bone histomorphometry. Bone 2001;28:556–62
   PubMed Web of Science ®Google Scholar
• Hodgson SF, Johnson KA, Muhs JM, Lufkin EG, McCarthy JT. Outpatient percutaneous biopsy of the iliac crest: methods, morbidity, and patient acceptance. Mayo Clinic Proc 1986; 61:28–33
   Google Scholar
• Thomsen JS, Ebbesen EN, Mosekilde L. Relationships between static histomorphometry and bone strength measurements in human iliac crest bone biopsies. Bone 1998;22:153–63
   Google Scholar
• Thomsen JS, Ebbesen EN, Mosekilde L. Static histomorphometry of human iliac crest and vertebral trabecular bone: a comparative study. Bone 2002;30:267–74
   Google Scholar
• Borah B, Dufresne TE, Chmielewski PA, Gross GJ, Prenger MC, Phipps RJ. Risedronate preserves trabecular architecture and increases bone strength in vertebra of ovariectomized minipigs as measured by three-dimensional microcomputed tomography. J Bone Miner Res 2002;17:1139–47
   PubMed Web of Science ®Google Scholar
• Ellenberg SS. Scientific and ethical issues in the use of placebo and active controls in clinical trials. J Bone Miner Res 2003;18:1121–4
   PubMed Web of Science ®Google Scholar
• Kanis JA, Oden A, Johnell O, Caulin F, Bone HG, Alexandre J-M, et al. Uncertain future of trials in osteoporosis. Osteoporos Int 2002;13:443–9
   PubMedGoogle Scholar
• Jones B, Jarvis P, Lewis JA, Ebbutt AF. Trials to assess equivalence: the importance of rigorous methods. Br Med J 1996;313:36–9
   PubMed Web of Science ®Google Scholar
• Kanis JA, Alexandre J-M, Bone HG, Abadie E, Brasseur D, Chassany O, et al. Study design in osteoporosis: a European perspective. J Bone Miner Res 2003;18:1133–8
   PubMed Web of Science ®Google Scholar
• Khosla S. Surrogates for fracture endpoints in clinical trials. J Bone Miner Res 2003;18:1146–9
   PubMed Web of Science ®Google Scholar
• Hochberg MC, Greenspan SL, Wasnich RD, Miller PD, Thompson DE, Ross PD. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 2002;87:1586–92
   PubMed Web of Science ®Google Scholar
• Wasnich RD, Miller PD. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 2000;85:231–6
   PubMed Web of Science ®Google Scholar
• Sarkar S, Reginster J-Y, Crans GG, Diez-Perez A, Pinette KV, Delmas PD. Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. J Bone Miner Res 2004;19:394–401
   Google Scholar
• Cummings SR, Black DM, Pearson JB, Karpf DB, Harris F, Genant HK, et al. How much of the reduction in risk of vertebral fractures by alendronate is explained by increased spine BMD? J Bone Miner Res 1999;14\(Suppl 1):S159 [Abstract]
   Google Scholar
• Shih J, Bauer DC, Orloff J, Capizzi T, Thompson D, Oppenheimer L, et al. Proportion of fracture risk reduction explained by BMD changes using Freedman analysis depends on choice of predictors. Osteoporos Int 2002;13(Suppl 3):S38–9
   Google Scholar
• Freedman LS, Graubard BI, Schatzkin A. Statistical validation of intermediate endpoints for chronic diseases. Stat Med 1992;11:167–78
   Google Scholar
• Wang Y, Taylor JMG. A measure of the proportion of treatment effect explained by a surrogate marker. Biometrics 2002;58:803–12
   PubMed Web of Science ®Google Scholar
• Lin DY, Fleming TR, de Gruttola V. Estimating the proportion of treatment effect explained by a surrogate marker. Stat Med 1997;16:1515–27
   Google Scholar
• Bycott PW, Taylor JMG. An evaluation of a measure of the proportion of the treatment effect explained by a surrogate marker. Control Clin Trials 1998;19:555–68
   PubMedGoogle Scholar
• Cranney A, Tugwell P, Zytaruk N, Robinson V, Weaver B, Adachi J, et al. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. Endocr Rev 2002;23:524–28
   Google Scholar
• Cranney A, Wells G, Willan A, Griffith L, Zytaruk N, Robinson V, et al. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 2002;23:508–16
   Google Scholar
• Cranney A, Tugwell P, Adachi J, Weaver B, Zytaruk N, Papaioannou A, et al. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 2002;23:517–23
   Google Scholar
• Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C, et al. IX. Summary of meta-analysis of therapies for postmenopausal osteoporosis. Endocr Rev 2002;23:570–8
   Google Scholar
• Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535–41
   PubMed Web of Science ®Google Scholar
• Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280:2077–82
   Google Scholar
• Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999;282:637–45
   PubMed Web of Science ®Google Scholar
• Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 1999;282: 1344–52
   PubMed Web of Science ®Google Scholar
• Liberman UA, Weiss SR, Broli J, Minne HW, Quan H, Bell NH, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995;333:1437–43
   PubMed Web of Science ®Google Scholar
• Reginster J-Y, Minne HW, Sorensen OH, Hooper M, Roux C, Brandt ML, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000;11:83–91
   Google Scholar
• Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004;350:1189–99
   PubMed Web of Science ®Google Scholar
• Sorensen OH, Crawford GM, Mulder H, Hosking DJ, Gennari C, Mellstrom D, et al. Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone 2003;32:120–6
   PubMed Web of Science ®Google Scholar
• Mellstrom DD, Sorensen OH, Goemaere S, Roux C, Johnson TD, Chines AA. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 2004;75:462–8
   PubMed Web of Science ®Google Scholar
• Greenspan SL, Emkey RD, Bone HG, Weiss SR, Bell NH, Downs RW Jr, et al. Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002;137:875–83
   Google Scholar
• Tremollieres FA, Pouilles J-M, Ribot C. Withdrawal of hormone replacement therapy is associated with significant vertebral bone loss in postmenopausal women. Osteoporos Int 2001;12:385–90
   Google Scholar
• Dufresne TE, Chmielewski PA, Manhart MD, Johnson TD, Borah B. Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography. Calcif Tissue Int 2003;73: 423–32
   Google Scholar
• Yates J, Barrett-Connor E, Barlas S, Chen Y-T, Siris ES. Rapid loss of hip fracture protection after estrogen cessation: evidence from the National Osteoporosis Risk Assessment. Obstet Gynecol 2004;103:440–6
   PubMed Web of Science ®Google Scholar
• Schnitzer T, Bone HG, Crepaldi G, Adami S, McClung M, Kiel D, et al. Therapeutic equivalence of alendronate 70mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging Clin Exp Res 2000;12:1–12
   Web of Science ®Google Scholar
• Brown JP, Kendler DL, McClung MR, Emkey RD, Adachi JD, Bolognese MA, et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 2002;71:103–11
   PubMed Web of Science ®Google Scholar
• Downs RW Jr, Bell NH, Ettinger MP, Walsh BW, Favus MJ, Mako B, et al. Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women. J Clin Endocrinol Metab 2000;85:1783–8
   PubMed Web of Science ®Google Scholar
• Dursin N, Dursin E, Yalcin S. Comparison of alendronate, calcitonin and calcium treatments in postmenopausal osteoporosis. Int J Clin Pract 2001;55:505–9
   Google Scholar
• Hosking D, Adami S, Felsenberg D, Andia JC, Valimaki M, Benhamou L, et al. Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study. Curr Med Res Opinion 2003;19:383–94
   PubMed Web of Science ®Google Scholar
• Sambrook PN, Geusens P, Ribot C, Solimano JA, Ferrer-Barriendos J, Gaines K, et al. Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (EFficacy of FOSAMAX versus EVISTA Comparison Trial) International. J Intern Med 2004;255:503–11
   Google Scholar
• Luckey M, Kagan R, Greenspan S, Bone H, Kiel DP, Simon J, et al. Once-weekly alendronate 70mg and raloxifene 60mg daily in the treatment of postmenopausal osteoporosis. Menopause 2004;11:405–15
   PubMed Web of Science ®Google Scholar
• Ravn P, Bidstrup M, Wasnich RD, Davis JW, McClung MR, Balske A, et al. Alendronate and estrogen-progestin in the longterm prevention of bone loss: four-year results from the Early Postmenopausal Intervention Cohort Study. Ann Intern Med 1999;131:935–42
   PubMed Web of Science ®Google Scholar
• Greenspan SL, Resnick NM, Parker RA. Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial. JAMA 2003;289:2525–33
   Google Scholar
• Bone HG, Greenspan SL, McKeever C, Bell N, Davidson M, Downs RW, et al. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. J Clin Endocrinol Metab 2000;85:720–6
   PubMed Web of Science ®Google Scholar
• Rosen CJ, Hochberg M, Bonnick S, McClung M, Miller P, Broy S, et al. Treatment with once-weekly alendronate 70mg compared to once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized, double-blind study. J Bone Miner Res 2004;20:141–51
   PubMed Web of Science ®Google Scholar
• Parfitt AM. Use of bisphosphonates in the prevention of bone loss and fractures. Am J Medicine 1991; 91(Suppl 5B): 42S–46S
   Google Scholar